184 related articles for article (PubMed ID: 33083218)
1. Primary bone lymphoma: Clinical presentation and therapeutic considerations.
Müller A; Dreyling M; Roeder F; Baur-Melnyk A; Knösel T; Klein A; Birkenmaier C; Jansson V; Dürr HR
J Bone Oncol; 2020 Dec; 25():100326. PubMed ID: 33083218
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
[TBL] [Abstract][Full Text] [Related]
4. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
5. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.
Ramadan KM; Shenkier T; Sehn LH; Gascoyne RD; Connors JM
Ann Oncol; 2007 Jan; 18(1):129-135. PubMed ID: 17018705
[TBL] [Abstract][Full Text] [Related]
6. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
[TBL] [Abstract][Full Text] [Related]
7. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
8. [Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma].
Zhong KL; Cao BP; Guo XC; Huang LF; Wang WX; Wang B; Zhang WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):126-130. PubMed ID: 35123614
[TBL] [Abstract][Full Text] [Related]
9. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
10. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
12. Malignant lymphoma of bone.
Dürr HR; Müller PE; Hiller E; Maier M; Baur A; Jansson V; Refior HJ
Arch Orthop Trauma Surg; 2002 Feb; 122(1):10-6. PubMed ID: 11995873
[TBL] [Abstract][Full Text] [Related]
13. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
15. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
[No Abstract] [Full Text] [Related]
18. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
19. Primary Bone Lymphoma: An Experience of a Regional Cancer Center from India.
Mahajan R; Yadav BS; Sharma SC; Gupta A; Kumar S
South Asian J Cancer; 2020 Oct; 9(4):227-229. PubMed ID: 34131574
[No Abstract] [Full Text] [Related]
20. Primary Bone Lymphoma: A 13 Year Retrospective Institutional Analysis in the Chemo-Immunotherapy Era.
Sharma A; Ahmed R; Agrawal N; Kapoor J; Sharma A; Khushoo V; Agrawal P; Bhurani D; Mirgh SP
Indian J Hematol Blood Transfus; 2021 Apr; 37(2):240-248. PubMed ID: 33867730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]